Cargando…
Apoptotic Death of Prostate Cancer Cells by a Gonadotropin-Releasing Hormone-II Antagonist
Gonadotropin-releasing hormone-I (GnRH-I) has attracted strong attention as a hormonal therapeutic tool, particularly for androgen-dependent prostate cancer patients. However, the androgen-independency of the cancer in advanced stages has spurred researchers to look for new medical treatments. In pr...
Autores principales: | Park, Sumi, Han, Ji Man, Cheon, Jun, Hwang, Jong-Ik, Seong, Jae Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057422/ https://www.ncbi.nlm.nih.gov/pubmed/24926857 http://dx.doi.org/10.1371/journal.pone.0099723 |
Ejemplares similares
-
Molecular Coevolution of Neuropeptides Gonadotropin-Releasing Hormone and Kisspeptin with their Cognate G Protein-Coupled Receptors
por: Kim, Dong-Kyu, et al.
Publicado: (2012) -
A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018) -
Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer
por: Liu, Yi-Fu, et al.
Publicado: (2021) -
Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
por: Chwalisz, Kristof
Publicado: (2023) -
Editorial Comment to Considerations for the use of gonadotropin‐releasing hormone agonists and antagonists in patients with prostate cancer
por: Kawahara, Takashi
Publicado: (2020)